Review of cost–effectiveness studies of pegylated therapies for hepatitis C

References

• Lauer GM, Walker BD. Medical progress: hepatitis C virus infection. N. Engl. J. Med. 345(1), 41–52 (2001).
   PubMed Web of Science ®Google Scholar
• Friedrich M J. Third millennium challenge: hepatitis C. JAMA 282(3), 221–222 (1999).
   PubMed Web of Science ®Google Scholar
• Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341(8), 556–562 (1999).
   PubMed Web of Science ®Google Scholar
• Gross JB. Clinician’s guide to hepatitis C. Mayo Clinic Proc. 73(4), 355–361 (1998).
   PubMed Web of Science ®Google Scholar
• Liang TJ, Rehermann B, Seeff LB et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132(4), 296–305 (2000).
   PubMedGoogle Scholar
• Booth JC, O’Grady J, Neuberger J et al. Clinical guidelines on the management of hepatitis C. Gut 49(Suppl. 1), I1–I21 (2001).
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Balogun MA, Collins M, Balraj V. Laboratory surveillance of hepatitis C virus infection in England and Wales: 1992 to 1996. Commun. Dis. Public Health 1(2), 89–94 (1998).
   PubMedGoogle Scholar
• Shiell A, Law MG. The cost of hepatitis C and the cost–effectiveness of its prevention. Health Policy 58(2), 121–131 (2001).
   PubMed Web of Science ®Google Scholar
• Leigh JP, Bowlus CL, Leistikow BN et al. Cost of hepatitis C. Arch. Intern. Med.161(18), 2231–2237 (2001).
   PubMed Web of Science ®Google Scholar
• Wong JB, McQuillan GM, McHutchison JG et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am. J. Public Health 90(10), 1562–1569 (2000).
   PubMed Web of Science ®Google Scholar
• Nicklin DE, Schultz C, Brensinger CM et al. Current care of hepatitis C-positive patients by primary care physicians in an integrated delivery system. J. Am. Board Fam. Pract. 12(6), 427–435 (1999).
   PubMedGoogle Scholar
• Gutfreund KS, Bain VG. Chronic viral hepatitis C: management update. CMAJ162(6), 827–833 (2000).
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Rossol S et al. Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut52(3), 425–432 (2003).
   PubMed Web of Science ®Google Scholar
• Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost–effectiveness analysis of peginterferon α-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 17(5), 687–694 (2003).
   PubMed Web of Science ®Google Scholar
• Kuehne FC, Bethe U, Freedberg K et al. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost–effectiveness. Arch. Intern. Med. 162(22), 2545–2556 (2002).
   PubMed Web of Science ®Google Scholar
• Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost–effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 290(2), 228–237 (2003).
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Craxi A, Alberti A et al. Cost–effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin as initial therapy for treatment-naïve chronic hepatitus C. Pharmacoeconomics 22(4), 257–265 (2004).
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Jensen DM, Bernstein DE et al. Cost–effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C. Am. J. Gastroenterol. 99(8), 1490–1496 (2004).
   PubMed Web of Science ®Google Scholar
• Bernstein D, Kleinman L, Barker CM et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 35(3), 704–708 (2002).
   PubMed Web of Science ®Google Scholar
• Rasenack J, Zeuzem S, Feinman SV et al. Peginterferon α-2a (40kD) (Pegasys) improves HR-QOL outcomes compared with unmodified interferon α-2a (roferon-A): in patients with chronic hepatitis C. Pharmacoeconomics 21(5), 341–349 (2003).
   PubMed Web of Science ®Google Scholar
• Perrillo R, Rothstein KD, Rubin R et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon α 2a vs. the combination of interferon α 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J. Viral Hepat. 11(2), 157–165 (2004).
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Gilroy RK, McCashland TM et al. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study. Transplant. Proc. 35(4), 1478–1479 (2003).
   PubMed Web of Science ®Google Scholar
• Mullins CD, Blak BT, Akhras, KS. Comparing cost–effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible? Value Health 5(4), 359–371 (2002).
   PubMed Web of Science ®Google Scholar
• Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282(5386), 103–107 (1998).
   PubMed Web of Science ®Google Scholar
  Hadziyannis SJ, Cheinquer T, Morgan M et al. Peginterferon alfa-2a (40KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a Phase III, randomized, double-blind, multicentre study examining effect of duration and RBV dose. 37th Annual Meeting of the European Association for the Study of the Liver.Madrid, Spain, April 18-21, 2002.
   Google Scholar
• Perelson AS, Essunger P, Cao Y et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387(6629), 188–191 (1997).
   PubMed Web of Science ®Google Scholar
• Perelson AS, Neumann AU, Markowitz M et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271(5255), 1582–1586 (1996).
   PubMed Web of Science ®Google Scholar
• Lesko SM, Mitchell AA. The use of randomized clinical trials for pharmacoepidemiological studies. In: Pharmacoepidemiology, Third Edition. John Wiley and Sons, Chichester, UK, 539–552 (2000).
   Google Scholar